AstraZeneca PLC ADS Community Page | What other sites are saying about AstraZeneca PLC ADS

AstraZeneca PLC ADS

(NY: AZN)

52.35 USD +0.64 (+1.24%)

Official Closing Price / Updated: 4:15 PM EDT, May 22, 2013 / Add to My Watchlist

(AZN) Community Analysis from

READ MORE (AZN)

Bulls REASONS TO BUY

75% agree 29 votes	MedImmune acquistion will provide long term pipeline
50% agree 2 votes	AstraZeneca has a highly profitable portfolio of young medicines

View all Bulls Reasons

Bears REASONS TO SELL

42% agree 14 votes	AstraZeneca experienced several setbacks in phase III drugs in 2006
20% agree 5 votes	Is AstraZeneca's Pipeline Running Dry?
28% agree 7 votes	MedImmune acquistion - too high a price paid?

View all Bears Reasons

Related Wikinvest articles

May 22, 2013

(AZN) AstraZeneca Inks Biomarker Discovery Deal

(Stock Blog Hub, 5/9/13)

AstraZeneca (AZN) recently announced that it has entered into an agreement with UK-based company, Oxford Cancer Biomarkers Ltd. As per the terms of the agreement, Oxford Cancer...(read more)

(AZN) AstraZeneca to Revamp Research and Development Structure

(Stock Blog Hub, 4/1/13)

AstraZeneca (AZN) recently announced that it plans to initiate strategic reforms in its research and development (R&D) segment. As per proposed plans, the...(read more)

Biotech Cancer Drug Partnership

(Wealth Daily, 4/24/13)

Pharmaceutical company AstraZeneca (NYSE:AZN) is betting big on a small biotech company's technology...

View all posts about AstraZeneca (AZN)

AstraZeneca (AZN) Company Overview

‎

AstraZeneca is one of the world's largest pharmaceutical companies, with FY2009 sales of $32.8 billion and $7.5 billion in profits.^[1] AstraZeneca's wide-ranging portfolio of products includes some of the world's most successful drugs. Among other blockbusters, AstraZeneca produces cholesterol fighter Crestor and the ubiquitous "purple pill" Nexium, one of the best-selling drugs in history.

(Read more at Wikinvest

)

What's in this AZN analysis on Wikinvest...